10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RNF125 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP59196

Product Information

Application	WB, IHC-P, IHC-F, IF, E
Primary Accession	Q96EQ8
Reactivity	Rat, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	26454
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human TRAC1/RNF125
Epitope Specificity	1-100/232
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Contains 1 RING-type zinc finger.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	The RING-type zinc finger motif is present in a number of viral and eukaryotic proteins and is made of a conserved cysteine-rich domain that is able to bind two zinc atoms. Proteins that contain this conserved domain are generally involved in the ubiquitination pathway of protein degradation. TRAC-1 (T-cell RING activation protein 1), also known as RNF125 (ring finger protein 125) or E3 ubiquitin-protein ligase RNF125, is a 232 amino acid novel E3 ubiquitin ligase that functions as a positive regulator in the T-cell receptor signaling pathway. Expressed predominantly in lymphoid tissues such as spleen, thymus and bone marrow, TRAC-1 has been found to inhibit pathogen-induced cytokine production and down-regulates HIV replication.

Additional Information

Gene ID	54941
Other Names	E3 ubiquitin-protein ligase RNF125, 2.3.2.27, RING finger protein 125 {ECO:0000312|HGNC:HGNC:21150}, T-cell RING activation protein 1, TRAC-1, RNF125 (HGNC:21150)
Target/Specificity	Predominantly expressed in lymphoid tissues, including bone marrow, spleen and thymus. Also weakly expressed in other tissues. Predominant in the CD4+ and CD8+ T-cells, suggesting that it is preferentially confined to T-cells.
Dilution	WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:50-200,ELISA=1:5000-10000

Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	RNF125 (HGNC:21150)
Function	E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins, such as RIGI, MAVS/IPS1, IFIH1/MDA5, JAK1 and p53/TP53 (PubMed:15843525, PubMed:17460044, PubMed:17643463, PubMed:25591766, PubMed:26027934, PubMed:26471729, PubMed:27411375). Acts as a negative regulator of type I interferon production by mediating ubiquitination of RIGI at 'Lys- 181', leading to RIGI degradation (PubMed:17460044, PubMed:26471729). Mediates ubiquitination and subsequent degradation of p53/TP53 (PubMed:25591766). Mediates ubiquitination and subsequent degradation of JAK1 (PubMed:26027934). Acts as a positive regulator of T-cell activation (PubMed:15843525).
Cellular Location	Golgi apparatus membrane; Lipid-anchor. Note=Shows a reticular staining pattern within the cell and is probably expressed at other intracellular membranes in addition to the Golgi membrane. Not detected at the plasma membrane.
Tissue Location	Predominantly expressed in lymphoid tissues, including bone marrow, spleen and thymus. Also weakly expressed in other tissues. Predominant in the CD4(+) and CD8(+) T-cells, suggesting that it is preferentially confined to T-cells